ClinicalTrials.gg
CompletedNCT02601001Updated Jul 27, 2021Results posted

Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults

A Phase 1 interventional study of Omecamtiv mecarbil and Placebo in Healthy Volunteer, sponsored by Cytokinetics. Completed at 1 site in Japan. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-27.

Sponsored by Cytokinetics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing omecamtiv mecarbil in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. omecamtiv mecarbil · Heart Failure.

Enrollment
7th of 14
50 · median 48
Started
2015
the only one that year
Phase 1
3 of 14
none open now
Registered
9th of 14
by date
Lead sponsor
14 of 14
Cytokinetics

Among the 14 studies testing omecamtiv mecarbil in Heart Failure, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 1, and was the 9th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 14 studies testing omecamtiv mecarbil in Heart Failure is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About omecamtiv mecarbil

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 20 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing omecamtiv mecarbil in Heart Failure, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of omecamtiv mecarbil in healthy volunteers in Japan.

Read the detailed description

This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.

03

Conditions studied

  • Healthy Volunteer

Browse trials for

Keywords

  • Heart failure
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No history or evidence of medical disorders as determined by the Investigator, and in good health as determined by a pre-study physical examination and medical history with no clinically significant abnormalities, normal vital signs and no history or presence of a clinically significant abnormal finding
  • Subjects' pre-study clinical laboratory findings (including creatine phosphokinase) should be within normal range or if outside of the normal range, are deemed not clinically significant by the Investigator.

Exclusion criteria

Exclusion Criteria:

  • A disorder/disease, including gastro intestinal abnormalities that might interfere with absorption
  • An unstable medical condition, defined as having been hospitalized within 28 days before day 1, major surgery within 6 months before day 1, or otherwise unstable in the judgment of the Investigator
  • History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the Investigator or Medical Monitor would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion
  • History of of any type other than surgically excised non-melanomatous skin cancers or in situ cervical cancer within 5 years before the day of dosing
  • Use of any prescription or over-the-counter medications within 14 days or 5 half-lives (whichever time period is greater), prior to receiving the first dose of omecamtiv mecarbil (acetaminophen up to 2 grams per day for analgesia and hormone replacement therapy (e.g., estrogen) will be allowed
  • Use of any known inhibitors of /p-glycoprotein (P-gp) or CYP2D6 within 14 days or 5 half-lives, whichever is longer; or use of grapefruit juice or grapefruit containing products within 7 days prior to receiving the first dose of omecamtiv mecarbil
  • Use of any known CYP3A4 inducers within 30 days or 5 half-lives, whichever is longer, before receiving omecamtiv mecarbil
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).

    Drug: Placebo

  • Experimental
    Omecamtiv mecarbil 25 mg / 37.5 mg

    Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was \< 200 ng/mL, participants received 37.5 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.

    Drug: Omecamtiv mecarbil

  • Experimental
    Omecamtiv mecarbil 25 mg / 50 mg

    Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was \< 200 ng/mL, participants received 50 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.

    Drug: Omecamtiv mecarbil

Interventions

  • Omecamtiv mecarbil tablets for oral administration

    Also known as: AMG 423

  • DrugPlacebo

    Matching placebo tablets

06

What researchers measure

Primary outcomes

  1. Dosing Period 1: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1

    Time frame: Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.

  2. Dosing Period 1: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1

    Time frame: Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.

  3. Dosing Period 1: Area Under the Concentration-time Curve for a Dosing Interval of 12 Hours (AUC0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 1

    Time frame: Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.

  4. Dosing Period 1: Predose Omecamtiv Mecarbil Plasma Concentration

    Time frame: Day 8 predose

  5. Dosing Period 1: Accumulation Ratio

    Accumulation ratio calculated as the ratio of day 8 AUC(0-12) / day 1 AUC(0-12)

    Time frame: Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.

  6. Dosing Period 2: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2

    Time frame: Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.

  7. Dosing Period 2: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2

    Time frame: Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.

  8. Dosing Period 2: AUC(0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 2

    Time frame: Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.

  9. Dosing Period 2: Predose Omecamtiv Mecarbil Plasma Concentration

    Time frame: Day 27 predose

  10. Dosing Period 2: Accumulation Ratio

    Accumulation ratio calculated as the ratio of day 27 AUC(0-12) / day 20 AUC(0-12).

    Time frame: Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events

    An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. Adverse events were graded for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

    Time frame: 35 days

  2. Number of Participants With Grade 3 or Higher Laboratory Toxicities

    Abnormal laboratory findings were graded for severity according to the NCI CTCAE version 4.0 according to the following guideline: * Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. * Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). * Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. * Grade 4: Life-threatening consequences; urgent intervention indicated. * Grade 5: Death related to AE.

    Time frame: 35 days

  3. Maximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 1

    QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by electrocardiogram (ECG). Maximum increase from Period 1 baseline was categorized as: ≤ 30 milliseconds (ms) \> 30 to 60 ms \> 60 ms

    Time frame: Day 1 predose and day 8

  4. Maximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 2

    QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by ECG. Maximum increase from Period 2 baseline was categorized as: ≤ 30 ms \> 30 to 60 ms \> 60 ms

    Time frame: Day 20 predose and Day 27

07

Results

Posted May 18, 2021

Participant flow

This study was conducted at a single center in Japan. Participants were enrolled from 13 November 2015 to 24 November 2015.

Dosing Period 1
Participant flow — Dosing Period 1
MilestonePlaceboPeriod 1 Group A: Omecamtiv Mecarbil 25 mgPeriod 1 Group B: Omecamtiv Mecarbil 25 mgPeriod 2 Group A: Omecamtiv Mecarbil 25 mgPeriod 2 Group A: Omecamtiv Mecarbil 37.5 mgPeriod 2 Group B: Omecamtiv Mecarbil 25 mgPeriod 2 Group B: Omecamtiv Mecarbil 50 mg
Started1020200000
Completed1020200000
Not completed0000000
Dosing Period 2
Participant flow — Dosing Period 2
MilestonePlaceboPeriod 1 Group A: Omecamtiv Mecarbil 25 mgPeriod 1 Group B: Omecamtiv Mecarbil 25 mgPeriod 2 Group A: Omecamtiv Mecarbil 25 mgPeriod 2 Group A: Omecamtiv Mecarbil 37.5 mgPeriod 2 Group B: Omecamtiv Mecarbil 25 mgPeriod 2 Group B: Omecamtiv Mecarbil 50 mg
Started1000713713
Completed1000713712
Not completed0000001
Withdrew: Adverse event0000001

Outcome measures

PrimaryDosing Period 1: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1
Time frame:
Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.
Reported as:
Mean · ng/mL
Dosing Period 1: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1
ng/mLGroup A: Omecamtiv Mecarbil 25 mgGroup B: Omecamtiv Mecarbil 25 mg
After first dose on day 177.4 ± 21.679.5 ± 18.9
After last dose on day 8256 ± 71.2259 ± 59.2
PrimaryDosing Period 1: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1
Time frame:
Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.
Reported as:
Median · hours
Dosing Period 1: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1
hoursGroup A: Omecamtiv Mecarbil 25 mgGroup B: Omecamtiv Mecarbil 25 mg
After first dose on day 14.0 (0.5 to 8.0)3.0 (0.5 to 8.0)
After last dose on day 82.0 (0.5 to 4.0)2.0 (0.5 to 8.0)
PrimaryDosing Period 1: Area Under the Concentration-time Curve for a Dosing Interval of 12 Hours (AUC0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 1
Time frame:
Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.
Reported as:
Mean · ng*hr/mL
Dosing Period 1: Area Under the Concentration-time Curve for a Dosing Interval of 12 Hours (AUC0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 1
ng*hr/mLGroup A: Omecamtiv Mecarbil 25 mgGroup B: Omecamtiv Mecarbil 25 mg
After first dose on day 1687 ± 210677 ± 163
After last dose on day 82570 ± 7392670 ± 699
PrimaryDosing Period 1: Predose Omecamtiv Mecarbil Plasma Concentration
Time frame:
Day 8 predose
Reported as:
Mean · ng/mL
Dosing Period 1: Predose Omecamtiv Mecarbil Plasma Concentration
ng/mLGroup A: Omecamtiv Mecarbil 25 mgGroup B: Omecamtiv Mecarbil 25 mg
Dosing Period 1: Predose Omecamtiv Mecarbil Plasma Concentration190 ± 58.5192 ± 55.1
PrimaryDosing Period 1: Accumulation Ratio

Accumulation ratio calculated as the ratio of day 8 AUC(0-12) / day 1 AUC(0-12)

Time frame:
Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.
Reported as:
Mean · ratio
Dosing Period 1: Accumulation Ratio
ratioGroup A: Omecamtiv Mecarbil 25 mgGroup B: Omecamtiv Mecarbil 25 mg
Dosing Period 1: Accumulation Ratio3.66 ± 0.893.79 ± 0.77
PrimaryDosing Period 2: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2
Time frame:
Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.
Reported as:
Mean · ng/mL
Dosing Period 2: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2
ng/mLGroup A: Omecamtiv Mecarbil 25 mg / 25 mgGroup A: Omecamtiv Mecarbil 25 mg / 37.5 mgGroup B: Omecamtiv Mecarbil 25 mg / 25 mgGroup B: Omecamtiv Mecarbil 25 mg / 50 mg
After first dose on day 2096.5 ± 27.2107 ± 30.484.9 ± 30.0154 ± 22.0
After last dose on day 27335 ± 32.0341 ± 48.8311 ± 54.2537 ± 91.7
PrimaryDosing Period 2: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2
Time frame:
Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.
Reported as:
Median · hours
Dosing Period 2: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2
hoursGroup A: Omecamtiv Mecarbil 25 mg / 25 mgGroup A: Omecamtiv Mecarbil 25 mg / 37.5 mgGroup B: Omecamtiv Mecarbil 25 mg / 25 mgGroup B: Omecamtiv Mecarbil 25 mg / 50 mg
After first dose on day 204.0 (2.0 to 11)2.0 (0.5 to 6.0)4.0 (1.0 to 11)3.0 (0.5 to 6.0)
After last dose on day 272.0 (0.5 to 4.0)3.0 (0.5 to 4.0)4.0 (0.5 to 4.0)3.0 (0.5 to 4.0)
PrimaryDosing Period 2: AUC(0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 2
Time frame:
Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.
Reported as:
Mean · ng*hr/mL
Dosing Period 2: AUC(0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 2
ng*hr/mLGroup A: Omecamtiv Mecarbil 25 mg / 25 mgGroup A: Omecamtiv Mecarbil 25 mg / 37.5 mgGroup B: Omecamtiv Mecarbil 25 mg / 25 mgGroup B: Omecamtiv Mecarbil 25 mg / 50 mg
After first dose on day 20902 ± 220950 ± 228841 ± 4031330 ± 217
After last dose on day 273520 ± 5053500 ± 5193290 ± 6625490 ± 1000
PrimaryDosing Period 2: Predose Omecamtiv Mecarbil Plasma Concentration
Time frame:
Day 27 predose
Reported as:
Mean · ng/mL
Dosing Period 2: Predose Omecamtiv Mecarbil Plasma Concentration
ng/mLGroup A: Omecamtiv Mecarbil 25 mg / 25 mgGroup A: Omecamtiv Mecarbil 25 mg / 37.5 mgGroup B: Omecamtiv Mecarbil 25 mg / 25 mgGroup B: Omecamtiv Mecarbil 25 mg / 50 mg
Dosing Period 2: Predose Omecamtiv Mecarbil Plasma Concentration271 ± 44.8256 ± 42.1245 ± 43.3401 ± 77.8
PrimaryDosing Period 2: Accumulation Ratio

Accumulation ratio calculated as the ratio of day 27 AUC(0-12) / day 20 AUC(0-12).

Time frame:
Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.
Reported as:
Mean · ratio
Dosing Period 2: Accumulation Ratio
ratioGroup A: Omecamtiv Mecarbil 25 mg / 25 mgGroup A: Omecamtiv Mecarbil 25 mg / 37.5 mgGroup B: Omecamtiv Mecarbil 25 mg / 25 mgGroup B: Omecamtiv Mecarbil 25 mg / 50 mg
Dosing Period 2: Accumulation Ratio4.12 ± 1.283.81 ± 0.834.53 ± 1.194.11 ± 1.15
SecondaryNumber of Participants With Treatment-emergent Adverse Events

An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. Adverse events were graded for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Time frame:
35 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsPlaceboGroup A: Omecamtiv Mecarbil 25 mg / 25 mgGroup A: Omecamtiv Mecarbil 25 mg / 37.5 mgGroup B: Omecamtiv Mecarbil 25 mg / 25 mgGroup B: Omecamtiv Mecarbil 25 mg / 50 mg
Any treatment-emergent adverse event64743
Serious adverse events00000
TEAE leading to discontinuation of study drug00001
Severe adverse events00011
Life-threatening adverse events00000
Fatal adverse events00000
SecondaryNumber of Participants With Grade 3 or Higher Laboratory Toxicities

Abnormal laboratory findings were graded for severity according to the NCI CTCAE version 4.0 according to the following guideline: * Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. * Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). * Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. * Grade 4: Life-threatening consequences; urgent intervention indicated. * Grade 5: Death related to AE.

Time frame:
35 days
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Higher Laboratory Toxicities
ParticipantsPlaceboGroup A: Omecamtiv Mecarbil 25 mg / 25 mgGroup A: Omecamtiv Mecarbil 25 mg / 37.5 mgGroup B: Omecamtiv Mecarbil 25 mg / 25 mgGroup B: Omecamtiv Mecarbil 25 mg / 50 mg
Number of Participants With Grade 3 or Higher Laboratory Toxicities00000
SecondaryMaximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 1

QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by electrocardiogram (ECG). Maximum increase from Period 1 baseline was categorized as: ≤ 30 milliseconds (ms) \> 30 to 60 ms \> 60 ms

Time frame:
Day 1 predose and day 8
Reported as:
Count of participants · Participants
Maximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 1
ParticipantsPlaceboGroup A: Omecamtiv Mecarbil 25 mg / 25 mgGroup A: Omecamtiv Mecarbil 25 mg / 37.5 mgGroup B: Omecamtiv Mecarbil 25 mg / 25 mgGroup B: Omecamtiv Mecarbil 25 mg / 50 mg
≤ 30 ms10713713
> 30 to 60 ms00000
> 60 ms00000
SecondaryMaximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 2

QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by ECG. Maximum increase from Period 2 baseline was categorized as: ≤ 30 ms \> 30 to 60 ms \> 60 ms

Time frame:
Day 20 predose and Day 27
Reported as:
Count of participants · Participants
Maximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 2
ParticipantsPlaceboGroup A: Omecamtiv Mecarbil 25 mg / 25 mgGroup A: Omecamtiv Mecarbil 25 mg / 37.5 mgGroup B: Omecamtiv Mecarbil 25 mg / 25 mgGroup B: Omecamtiv Mecarbil 25 mg / 50 mg
≤ 30 ms10713712
> 30 to 60 ms00000
> 60 ms00000

Adverse events

Collected over Period 1: Day 1 to day 19 Period 2: Day 20 to day 35. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Placebo—0/10 (0%)2/10 (20%)
Period 1 Group A: OM 25 mg BID—0/20 (0%)5/20 (25%)
Period 1 Group B: OM 25 mg BID—0/20 (0%)3/20 (15%)
Period 2: Placebo—0/10 (0%)4/10 (40%)
Period 2 Group A: OM 25 mg BID—0/7 (0%)3/7 (42.9%)
Period 2 Group A: OM 37.5 mg BID—0/13 (0%)3/13 (23.1%)
Period 2 Group B: OM 25 mg BID—0/7 (0%)1/7 (14.3%)
Period 2 Group B: OM 50 mg BID—0/13 (0%)3/13 (23.1%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPeriod 1: PlaceboPeriod 1 Group A: OM 25 mg BIDPeriod 1 Group B: OM 25 mg BIDPeriod 2: PlaceboPeriod 2 Group A: OM 25 mg BIDPeriod 2 Group A: OM 37.5 mg BIDPeriod 2 Group B: OM 25 mg BIDPeriod 2 Group B: OM 50 mg BID
Alanine aminotransferase increasedInvestigations0/102/200/202/101/73/130/71/13
Injection site nerve damageGeneral disorders0/100/200/200/100/70/131/70/13
Protein urine presentInvestigations0/100/200/200/101/70/130/70/13
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders0/102/200/200/101/70/130/70/13
Orthostatic hypotensionVascular disorders0/100/200/200/101/70/130/70/13
NauseaGastrointestinal disorders1/100/200/200/100/70/130/70/13
Chest painGeneral disorders0/100/200/201/100/70/130/70/13
Aspartate aminotransferase increasedInvestigations0/101/200/201/100/70/130/71/13
ArthralgiaMusculoskeletal and connective tissue disorders0/100/200/201/100/70/130/70/13
Back painMusculoskeletal and connective tissue disorders1/100/200/200/100/70/130/70/13

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)PlaceboGroup A: Omecamtiv Mecarbil 25 mg / 37.5 mgGroup B: Omecamtiv Mecarbil 25 mg / 50 mgTotal
Mean29.2 ± 4.235.5 ± 7.627.3 ± 4.631.0 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGroup A: Omecamtiv Mecarbil 25 mg / 37.5 mgGroup B: Omecamtiv Mecarbil 25 mg / 50 mgTotal
Female36615
Male7141435
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboGroup A: Omecamtiv Mecarbil 25 mg / 37.5 mgGroup B: Omecamtiv Mecarbil 25 mg / 50 mgTotal
Hispanic or Latino0000
Not Hispanic or Latino10202050
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboGroup A: Omecamtiv Mecarbil 25 mg / 37.5 mgGroup B: Omecamtiv Mecarbil 25 mg / 50 mgTotal
American Indian or Alaska Native0000
Asian10202050
Black or African American0000
Native Hawaiian or Other Pacific Islander0000
White0000
08

Study locations

1 site
  • Research Site
    Kagoshima-shi, Kagoshima 890-0081, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Jan 2016, 1 month.

Results were first posted in May 2021, 5 years 4 months after primary completion.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2015
First posted
Nov 10, 2015
StartActual
Nov 13, 2015
Primary completionActual
Jan 6, 2016
CompletionActual
Jan 6, 2016
Results first posted
May 18, 2021
Last update
Jul 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02601001
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
Nov 10, 2015
Start date
Nov 13, 2015
Primary completion
Jan 6, 2016
Completion
Jan 6, 2016
Results posted
May 18, 2021
Last update
Jul 27, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omecamtiv mecarbil

Start the discussion